Pharming Group N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
11 okt 2006 - 08:01
Statutaire naam
Pharming Group N.V.
Titel
NOVATHERA AND PHARMING PROGRESS NOVEL BIOACTIVE MATERIAL STUDIES AND PRODUCT DEVELOPMENT
Bericht
Cambridge, UK and Leiden, The Netherlands, October 11, 2006. NovaThera Limited (“NovaThera”) and biotech company Pharming Group NV (“Pharming”) (Euronext: PHARM) (PHARM.AS) today announce the successful completion of their proof of concept studies designed to develop a new generation of bioactive materials. These materials are based on a fusion of the two companies’ technologies - TheraGlass™ (a non-ceramic glass) and recombinant human proteins. The novel properties of such materials provide a new intellectual property portfolio for commercial exploitation.
TheraGlass-rH™ (TheraGlass™ with recombinant human proteins) has the potential to extend the therapeutic potential from transgenic technologies into the arena of medical devices and materials technologies. The new materials can be used for the localized delivery of therapeutic proteins and for developing devices such as stents and catheters.
The initial focus is on stents containing materials able to release recombinant human proteins such as collagen, fibrinogen, lactoferrin and C1 inhibitor. “The first transgenic protein products are now moving towards regulatory approval,” said Dr. Francis Pinto, CEO of Pharming. “Novel bioactive materials enable the development of a new generation of medical devices.”
“NovaThera is pleased with the progress made in developing these exciting new bioactive materials,” said Dr. Gareth Roberts, CEO of NovaThera. “We look forward to exploring their potential for the development of new therapeutically enabled medical devices.”
Background on NovaThera Ltd
NovaThera Ltd is an Imperial College spin out company. NovaThera specialises in pioneering applications of biomaterials and stem cell biology for regenerative medicines to provide innovative therapeutic solutions, like wound management, bone repair and lung repair. For more information about NovaThera, please visit http://www.novathera.com.
Background on Pharming Group NV
Pharming Group NV is developing innovative protein
Datum laatste update: 01 september 2024